Spots Global Cancer Trial Database for A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Official Title: A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
Study ID: NCT03706690
Conditions
Study Description
Brief Summary: This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.
Detailed Description: Approximately 400 patients will be randomized in a 2:1 to receive treatment with durvalumab or placebo therapy. The primary objective of this study is to assess the efficacy of durvalumab treatment compared with placebo in terms of PFS.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Bengbu, , China
Research Site, Changchun, , China
Research Site, Changsha, , China
Research Site, Chengdu, , China
Research Site, Chengdu, , China
Research Site, Chengdu, , China
Research Site, Chongqing, , China
Research Site, Fuzhou, , China
Research Site, Guangzhou, , China
Research Site, Guangzhou, , China
Research Site, Hangzhou, , China
Research Site, Hangzhou, , China
Research Site, Hangzhou, , China
Research Site, Harbin, , China
Research Site, Linhai, , China
Research Site, Nanjing, , China
Research Site, Nanning, , China
Research Site, Ningbo, , China
Research Site, Qingdao, , China
Research Site, Shanghai, , China
Research Site, Shanghai, , China
Research Site, Shanghai, , China
Research Site, Shenyang, , China
Research Site, Wenzhou, , China
Research Site, Wuhan, , China
Research Site, Yangzhou, , China
Research Site, Zhengzhou, , China
Research Site, Zhengzhou, , China
Research Site, Ürümqi, , China
Research Site, Hong Kong, , Hong Kong
Research Site, HongKong, , Hong Kong
Research Site, Bangalore, , India
Research Site, Bengaluru, , India
Research Site, Karamsad, , India
Research Site, Kolkata, , India
Research Site, Nasik, , India
Research Site, Vadodara, , India
Research Site, Daegu, , Korea, Republic of
Research Site, Gwangju, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Cdmx, , Mexico
Research Site, Culiacán, , Mexico
Research Site, Mexico City, , Mexico
Research Site, Monterrey, , Mexico
Research Site, México, , Mexico
Research Site, San Luis Potosí, , Mexico
Research Site, Bacolod, , Philippines
Research Site, Baguio City, , Philippines
Research Site, Cagayan De Oro City, , Philippines
Research Site, Cebu, , Philippines
Research Site, Davao City, , Philippines
Research Site, Quezon City, , Philippines
Research Site, Quezon City, , Philippines
Research Site, San Juan, , Philippines
Research Site, Białystok, , Poland
Research Site, Gdańsk, , Poland
Research Site, Poznań, , Poland
Research Site, Tomaszów Mazowiecki, , Poland
Research Site, Warszawa, , Poland
Research Site, Kazan, Tatarstan, , Russian Federation
Research Site, Kirov, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Murmansk, , Russian Federation
Research Site, Novosibirsk, , Russian Federation
Research Site, Novosibirsk, , Russian Federation
Research Site, Obninsk, , Russian Federation
Research Site, Saint Petersburg, , Russian Federation
Research Site, Samara, , Russian Federation
Research Site, Saransk, , Russian Federation
Research Site, Volgograd, , Russian Federation
Research Site, Taichung, , Taiwan
Research Site, Tainan, , Taiwan
Research Site, Taipei City, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taoyuan, , Taiwan
Research Site, Adana, , Turkey
Research Site, Ankara, , Turkey
Research Site, Edirne, , Turkey
Research Site, Istanbul, , Turkey
Research Site, Konya, , Turkey
Research Site, Malatya, , Turkey
Contact Details
Name: Yilong Wu, MD
Affiliation: Guangdong General Hospital, Guangdong Lung Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
